Andes, David R, Ghannoum, Mahmoud A, Mukherjee, Pranab K, Kovanda, Laura L ORCID: 0000-0002-4493-4652, Lu, Qiaoyang, Jones, Mark E, Henriksen, Anne Santerre, Lademacher, Christopher and Hope, William W ORCID: 0000-0001-6187-878X
(2019)
Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63 (1).
e01634-e01618.
Abstract
This pooled analysis evaluated the relationship of isavuconazole and voriconazole MICs of <i>Aspergillus</i> pathogens at baseline with all-cause mortality and clinical outcomes following treatment with either drug in the SECURE and VITAL trials. Isavuconazole and voriconazole may have had reduced efficacy against pathogens with drug MICs of ≥16 µg/ml, but there was no relationship with clinical outcomes in cases where the MIC was <16 µg/ml for either drug.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | MIC, clinical trial, isavuconazole, isavuconazonium sulfate, voriconazole |
Depositing User: | Symplectic Admin |
Date Deposited: | 17 Jan 2019 11:12 |
Last Modified: | 07 Feb 2024 15:35 |
DOI: | 10.1128/AAC.01634-18 |
Open Access URL: | https://aac.asm.org/content/63/1/e01634-18 |
Related URLs: | |
URI: | https://livrepository.liverpool.ac.uk/id/eprint/3031429 |